SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo Bioworks. This partnership, fully funded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, aims to accelerate the discovery and development of next-generation vaccine adjuvants to combat emerging viral, bacterial, and fungal threats.
“By overcoming the limitations of traditional molecular encoders, we are unlocking new possibilities in adjuvant development that can significantly advance SaponiQx and Ginkgo Bioworks in their quest to deliver new adjuvants to the warfighter.”
HealthTech Insights: AIRS Medical Partners with Starvision to Bring SwiftMR MRI Technology
The collaboration will integrate Probius’s proprietary Quantum Electrochemical Spectroscopy (QES) molecule characterization technology, which provides unique insights into the molecular physics of complex saponins, to enhance SaponiQx’s innovative adjuvant development platform. By integrating QES with high-throughput empirical biological and traditional physicochemical data, the team aims to mathematically represent complex saponins to train Generative Molecular Design AI algorithms, leading to the rapid identification of superior adjuvants.
“Teaming up with Probius and Ginkgo Bioworks represents a pivotal moment in our mission,” said Rebecca Kurnat, Head of Operations at SaponiQx. “With Probius’ cutting-edge technology, we are poised to deliver advanced capabilities to the warfighter and respond effectively to the challenges posed by emerging pathogens.”
HealthTech Insights: Selfii Announces TripleBlind Exchange, a First-of-its-Kind Marketplace Providing Access
QES functions as a universal molecular encoder, capturing detailed physics information that traditional methods cannot provide. QES structural signatures enable new in-silico correlations between saponin structures and biochemical outcomes, redefining the landscape of adjuvant discovery.
“Probius is excited to contribute our transformative QES technology to this collaboration,” said John Baldoni, PhD, Chief Scientific Officer at Probius. “By overcoming the limitations of traditional molecular encoders, we are unlocking new possibilities in adjuvant development that can significantly advance SaponiQx and Ginkgo Bioworks in their quest to deliver new adjuvants to the warfighter.”
HealthTech Insights: Hydreight and Victory Square Launch $10 Million Health Accelerator to Fuel Nationwide Expansion
With the proven success of Agenus‘ QS-21 Stimulon platform in currently approved vaccines for Shingles, Malaria, and RSV, this collaboration is set to pave the way for the rapid discovery and manufacturing of next-generation adjuvants. These innovative molecules are expected to meet the challenges posed by new and emerging pathogens in vaccine development, by improving the efficacy and durability of vaccines and thus ensuring our preparedness in the face of evolving biological threats.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – businesswire
